Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMMU

Immunomedics (IMMU) Stock Price, News & Analysis

Immunomedics logo

About Immunomedics Stock (NASDAQ:IMMU)

Advanced Chart

Key Stats

Today's Range
$87.86
$87.86
50-Day Range
$85.08
$87.86
52-Week Range
$8.80
$87.93
Volume
N/A
Average Volume
4.01 million shs
Market Capitalization
$20.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IMMU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMMU Stock News Headlines

Gilead Sciences Tops Estimates in Q3
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.tc pixel
Gilead Sciences Shows Strong Q3 Results Amid Strategic Initiatives
See More Headlines

IMMU Stock Analysis - Frequently Asked Questions

Immunomedics, Inc. (NASDAQ:IMMU) announced its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.39. The biopharmaceutical company had revenue of $20.07 million for the quarter, compared to analyst estimates of $24.81 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunomedics investors own include Bristol Myers Squibb (BMY), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Micron Technology (MU), Gilead Sciences (GILD) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2020
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMMU
CIK
722830
Fax
N/A
Employees
366
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$357.19 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-132.40%
Return on Assets
-51.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.84
Quick Ratio
12.58

Sales & Book Value

Annual Sales
$290 thousand
Price / Sales
70,028.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.38 per share
Price / Book
63.67

Miscellaneous

Outstanding Shares
231,144,000
Free Float
N/A
Market Cap
$20.31 billion
Optionable
Optionable
Beta
2.90
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IMMU) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners